News
Eli Lilly's Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback